PROGEN — Prostatype Genomics AB Balance Sheet
0.000.00%
- SEK13.01m
- SEK3.59m
- SEK0.20m
Annual balance sheet for Prostatype Genomics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15.9 | 20.3 | 11.5 | 2.68 | 9.42 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.915 | 0.65 | 2.16 | 22.7 | 2.31 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17.5 | 21.6 | 14.2 | 25.9 | 11.8 |
Net Property, Plant And Equipment | 0.028 | 0.014 | 0.004 | 0.06 | 0.312 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 33.7 | 40.2 | 31 | 49.2 | 42 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.31 | 3.43 | 4.33 | 24.5 | 8.5 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.37 | 4.3 | 4.8 | 24.5 | 8.5 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 28.3 | 35.9 | 26.2 | 24.7 | 33.5 |
Total Liabilities & Shareholders' Equity | 33.7 | 40.2 | 31 | 49.2 | 42 |
Total Common Shares Outstanding |